FIELD: medicine.
SUBSTANCE: invention refers to anti-inflammatory therapy of polypous rhinosinusitis, namely to application of an oral preparation containing ammonium glycyrrhizinate as an active ingredient in anti-inflammatory therapy of polypous rhinosinusitis.
EFFECT: invention provides a wider range of agents for the anti-inflammatory therapy of polypous rhinosinusitis, the pathogenetic target of which is the effective counteraction to the pro-inflammatory effects of HMGB1, that is clinically determined by reduction of the main symptoms of the disease (congestion, nasal discharge, et cetera), swelling of the nasal mucosa, absence of further growth and/or reduction of the size of polyps, improved control over the course of the disease.
5 cl, 7 tbl, 3 ex, 7 dwg
